Premium
Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis
Author(s) -
Renna S.,
Orlando E.,
Macaluso F. S.,
Maida M.,
Affronti M.,
Giunta M.,
Sapienza C.,
Rizzuto G.,
Orlando R.,
Dimarco M.,
Cottone M.,
Orlando A.
Publication year - 2016
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13692
Subject(s) - medicine , golimumab , adalimumab , ulcerative colitis , infliximab , gastroenterology , adverse effect , colitis , surgery , tumor necrosis factor alpha , disease
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom